SRPT Exec Transition — $576.7K Severance and Consulting Through Dec 31

Rhea-AI Filing Summary

Sarepta Therapeutics announced the planned departure of Bilal Arif, its Executive Vice President and Chief Technical Operations Officer, as part of a strategic restructuring and pipeline prioritization. Mr. Arif served in the role through August 12, 2025, will remain a Special Advisor until his employment ends on September 16, 2025, and will provide consulting services through December 31, 2025. The company and Mr. Arif executed a Separation and Consulting Agreement dated August 12, 2025, under which he will receive a lump-sum severance payment of $576,700 and a consulting fee of $400 per hour. Outstanding equity awards will continue to vest while he remains employed or provides consulting services. The full agreement will be filed as an exhibit to the Company’s Quarterly Report for the quarter ended September 30, 2025.

Positive

• Continuity preserved: Mr. Arif will consult through December 31, 2025, helping transition responsibilities.
• Equity alignment maintained: Outstanding equity awards will continue to vest while he is employed or consulting, preserving incentive alignment.

Negative

• Senior leadership departure: The company is losing its Executive Vice President, Chief Technical Operations Officer amid strategic restructuring.
• Separation cost disclosed: The agreement includes a lump-sum severance of $576,700 plus a consulting rate of $400 per hour.

Insights

Corporate Governance Expert

TL;DR: Senior operations leader departs during restructuring; separation includes severance and consulting to preserve continuity.

The filing documents a controlled executive transition tied to a stated strategic restructuring and pipeline prioritization. The Separation and Consulting Agreement provides continuity by extending vesting of equity awards and retaining Mr. Arif as a consultant through December 31, 2025, which may limit short-term disruption. The agreement’s explicit cash severance of $576,700 and a consulting rate of $400/hour are material compensation details that investors can quantify. Impact assessment: Neutral given mitigation steps and disclosed terms.

Operations / Technical Operations Specialist

TL;DR: Departure of Chief Technical Operations Officer is operationally significant but partially mitigated by consulting arrangement and continued equity vesting.

The departure of the Executive VP, Chief Technical Operations Officer, during a strategic reprioritization is an operational change that could affect technical programs. The company has secured consulting services through December 31, 2025 and continued vesting of outstanding equity awards while services continue, which preserves some leadership continuity and incentives. The disclosed financial terms—$576,700 severance plus $400/hour consulting—define the near-term cost of the transition. Impact assessment: Potentially impactful on operations but explicitly mitigated by the agreement.

false 0000873303 0000873303 2025-08-12 2025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

Sarepta Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-14895		93-0797222
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
215 First Street
Cambridge, Massachusetts				02142
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 274-4000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		SRPT		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with the strategic restructuring and pipeline prioritization of Sarepta Therapeutics, Inc. (the “Company”), Bilal Arif’s employment will end effective September 16, 2025. Mr. Arif served as the Executive Vice President, Chief Technical Operations Officer of the Company until August 12, 2025 and will serve as Special Advisor to the President for the remainder of his employment. The Company thanks Mr. Arif for his substantial contributions during a transformational period for the Company and wishes him well.

The Company entered into a Separation and Consulting Agreement and General Release (the “Agreement”) with Mr. Arif dated August 12, 2025, pursuant to which he will remain a consultant to the Company following his termination of employment through December 31, 2025. Pursuant to the terms of the applicable equity award agreements, the outstanding equity awards issued to Mr. Arif as of August 12, 2025 will continue to vest through the period in which Mr. Arif continues to be employed by or provide consulting services to the Company. Under the Agreement, the Company has agreed to pay Mr. Arif severance in the lump sum amount of $576,700 as well as a consulting fee of $400 per hour for the consulting services provided.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by the full text of the Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Sarepta Therapeutics, Inc.
Date: August 13, 2025				By:		/s/ Douglas S. Ingram
						Douglas S. Ingram Chief Executive Officer

FAQ

What change did Sarepta (SRPT) report regarding its executive team?

Sarepta reported that Bilal Arif, Executive Vice President and Chief Technical Operations Officer, will end his employment effective September 16, 2025 and will serve as a consultant through December 31, 2025.

How much severance will Sarepta pay to Bilal Arif?

The Separation Agreement provides for a lump-sum severance payment of $576,700.

Will Mr. Arif’s equity awards continue to vest after his departure?

Yes. Outstanding equity awards will continue to vest during the period in which Mr. Arif is employed by or provides consulting services to the Company.

What consulting compensation will Mr. Arif receive?

He will be paid a consulting fee of $400 per hour for services provided after termination of employment.

Will Sarepta file the full separation agreement for investor review?

Yes. The full Separation and Consulting Agreement will be filed as an exhibit to the Company’s Quarterly Report for the quarter ended September 30, 2025.